Remedium Capital Partners, LLC
Net buyer this quarter
$452M
6
+$1.12M
100.0%
Holdings
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026 | |||||
 ORKA | $149M | 32.99% | 2.56% | Not reported | Q4 2025 |
 SYRE | $130M | 28.78% | 1.66% | +0.6% | Q4 2025 |
| APGE | $77.9M | 17.24% | 0.78% | +0.5% | Q4 2025 |
 DMRA | $53.2M | 11.78% | 3.31% | Not reported | Q4 2025 |
 JBIO | $35.1M | 7.76% | 2.48% | Not reported | Q4 2025 |
 CBIO | $6.5M | 1.44% | 1.30% | Not reported | Q4 2025 |
| Q1 2026 | |||||
| ORKA | $76.8M | 27.31% | 3.12% | +0.9% | Q4 2025 |
| SYRE | $73.5M | 26.13% | 1.85% | Not reported | Q4 2025 |
| DMRA | $53M | 18.84% | 3.39% | +1597.9% | Q4 2025 |
| APGE | $49.1M | 17.47% | 0.78% | Not reported | Q4 2025 |
| JBIO | $22.2M | 7.88% | 3.20% | Not reported | Q4 2025 |
| CBIO | $6.64M | 2.36% | 1.31% | Not reported | Q4 2025 |
| Q4 2025 | |||||
| SYRE | $47.7M | 28.03% | 1.86% | New | Q4 2025 |
| ORKA | $47.1M | 27.64% | 3.19% | New | Q4 2025 |
| APGE | $44.1M | 25.88% | 0.85% | New | Q4 2025 |
| JBIO | $24.3M | 14.30% | 3.20% | New | Q4 2025 |
| CBIO | $4.28M | 2.52% | 1.31% | New | Q4 2025 |
| DMRA | $2.77M | 1.63% | 7.54% | New | Q4 2025 |